Prospective,Randomized,Study of Ampicillin-Sulbactam versus Moxifloxacin Monotherapy for the Treatment of Community-Acquired Complicated Intra-Abdominal Infections

Abstract

Background:

The ideal antimicrobial treatment for intra-abdominal infections (IAIs) in the setting of fast-paced emergency departments (EDs) should be effective, convenient, and of limited resource utilization. Antibiotic monotherapy is a feasible option for this. We conducted a study in which we compared two regimens for antibiotic monotherapy recommended by published guidelines in ED patients with community-acquired, complicated IAIs (cIAIs).

Methods:

The study was a prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin for cIAIs. After the diagnosis of cIAI was established, patients were assigned randomly to receive either moxifloxacin 400 mg intravenously (IV) qd followed by moxifloxacin 400 mg orally (PO) qd, or ampicillin-sulbactam 1.5 g IV qid followed by ampicillin-sulbactam 750 mg PO q12h. Source control procedures were used for all patients and all had complete follow-up. The primary efficacy variable for the study was the clinical response at the test-of-cure visit.

Results:

A total of 116 patients were enrolled for prospective evaluation and randomized assignment to treatment with ampicillin-sulbactam (n=55) or moxifloxacin (n=61). At the test-of-cure evaluation, the overall clinical failure rate was 13.8%. The clinical failure rates in the ampicillin-sulbactam and moxifloxacin groups were 16.4% (9/55) and 11.5% (7/61), respectively (p=0.446). With regard to infection site, the clinical failure rate in cIAIs consisting of lower gastrointestinal (GI) tract infection was significantly lower in the moxifloxacin than in the ampicillin-sulbactam group (4.3% vs. 19.6%; p=0.024). According to multivariable analysis, independent risk factors for treatment failure were the time to ED presentation >24 h (odds ratio [OR] 6.8; 95% CI 1.3-36.2; p=0.024) and ampicillin-sulbactam therapy (OR 9.5; 95% CI 1.1–76.6; p=0.033).

Conclusions:

A significant difference existed in the clinical responses of the two groups. As compared with ampicillin-sulbactam, moxifloxacin was more effective for the treatment of community-acquired cIAIs of the lower GI tract. A higher risk of treatment failure for antibiotic therapy was found for patients presenting to the ED with symptoms of cIAIs lasting >24 h. Alternative antimicrobial agents should be considered for treating these patients.

Get full access to this article

View all access options for this article.

References

Mazuski

. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother, 2007; 8:2933–2945.

Nadler

, Gaines

. The Surgical Infection Society guidelines on antimicrobial therapy for children with appendicitis. Surg Infect (Larchmt), 2008; 9:75–83.

Weigelt

. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med, 2007; 74,Suppl 4:S29–S37.

Solomkin

, Mazuski

, Baron

et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis, 2003; 37:997–1005.

Swenson

, Metzger

, Hedrick

et al.

Choosing antibiotics for intra-abdominal infections: what do we mean by “high risk”?

Surg Infect (Larchmt), 2009; 10:29–39.

Guidelines for antimicrobial therapy of intra-abdominal infections in adults. J Microbiol Immunol Infect, 2008; 41:279–281.

Hasper

, Schefold

, Baumgart

. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov, 2009; 4:57–65.

Solomkin

, Zhao

, Ma

et al. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents, 2009; 34:439–445.

Malangoni

, Song

, Herrington

et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg, 2006; 244:204–211.

10.

Weiss

, Reimnitz

, Hampel

et al.

Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study)

J Chemother, 2009; 21:170–180.

11.

Lin

H-L

, Kuo

L-C

, Chen

C-W

et al.

Reply to letter entitled “Timing and mode of surgery for inflammatory omental cyst questioned.”

J Formosan Med Assoc, 2009; 108:974–975.

12.

Schnuriger

, Inaba

, Eberle

et al. Microbiological profile and antimicrobial susceptibility in surgical site infections following hollow viscus injury. J Gastrointest Surg, 2010; 14:1304–1310.

13.

Betrosian

, Douzinas

. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol, 2009; 5:1099–1112.

14.

Lode

. Rational antibiotic therapy and the position of ampicillin-sulbactam. Int J Antimicrob Agents, 2008; 32:10–28.

15.

Bodmann

. [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antibiotic therapy] Chirurg, 2010; 81:38–49.

16.

Mazuski

, Solomkin

. Intra-abdominal infections. Surg Clin North Am, 2009; 89:421–437, ix.

17.

Solomkin

, Mazuski

, Bradley

et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt), 2010; 11:79–109.

18.

Falagas

, Barefoot

, Griffith

et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis, 1996; 15:913–921.

19.

Garnacho-Montero

, Garcia-Garmendia

, Barrero-Almodovar

et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med, 2003; 31:2742–2751.

20.

Siddiqui

, Salahuddin

, Raza

, Razzak

. How early do antibiotics have to be to impact mortality in severe sepsis? A prospective, observational study from an emergency department. J Ayub Med Coll Abbottabad, 2009; 21:106–110.

21.

Gaieski

, Mikkelsen

, Band

et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med, 2010; 38:1045–1053.